Company Overview - Outset Medical, Inc. is a medical technology company focused on pioneering technology to reduce the cost and complexity of dialysis [3] - The Tablo® Hemodialysis System is FDA cleared for use from the hospital to the home, representing a significant technological advancement in dialysis [3] - Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by anyone [3] Technological Innovation - The integration of water purification and on-demand dialysate production enables Tablo to function as a "dialysis clinic on wheels" [3] - Tablo features 2-way wireless data transmission and a proprietary data analytics platform, promoting a holistic approach to dialysis care [3] Upcoming Events - Members of Outset's management will participate in the RBC Capital Markets Global Health Care conference on May 20, 2025, at 10:30 a.m. Eastern time [1] - A live and archived webcast of the session will be available on the "Investors" section of the Outset website [2]

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2025, after the market close on May 13, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 p ...

MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments. Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our ...

Group 1 - Norsk Hydro ASA elected Kim Wahl as a new member of the Board of Directors for a term of up to two years, until the Annual General Meeting in 2027 [1] - Four employee representatives were elected on April 29, 2025, for a period of two years, until the next election in 2027 [2] - The Board of Directors now consists of 11 members following the elections held during the Annual General Meeting on May 9, 2025 [3] Group 2 - The current members of the Board of Directors include Rune Bjerke (chair), Kristin Fejerskov Kragseth (deputy chair), and Kim Wahl among others [4]

Core Insights - Xtreme One Entertainment, Inc. has entered into an exclusive Spanish-language rights agreement with CDN Deportes to broadcast Xtreme Fighting Championships (XFC) events in the Dominican Republic, enhancing its media presence and fan base [1][2][3] Company Overview - Xtreme One Entertainment, Inc. is a diversified holding company focused on media, entertainment, live sports, and event marketing, having acquired XFC Global in 2023 [7] - XFC has produced over 50 televised professional MMA events since 2006, with a significant viewership across various platforms [7] Partnership Details - The partnership with CDN Deportes will debut with the Young Guns 8 series, aimed at showcasing rising MMA prospects to an international audience [2][3] - CDN Deportes is the leading sports network in the Dominican Republic, providing national coverage and a platform for various sports, including XFC events [5][6] Audience Reach - The agreement with CDN Deportes allows XFC to reach over 1.3 million households in the Dominican Republic, significantly expanding its MMA fan base [2][3] - XFC's programming is also available on multiple platforms, including beIN SPORTS in the U.S. and Canada, BAND TV in Brazil, and its YouTube channel [3][7]

Core Viewpoint - SRx Health Solutions, Inc. is diversifying its asset allocation strategy by investing approximately $1.5 million in Solana Tokens (SOL) as part of a broader initiative to allocate up to 10% of future cash flows and cash reserves into cryptocurrencies and precious metals [1][2]. Group 1: Investment Strategy - The company plans to actively allocate a portion of its capital to cryptocurrencies, including Solana and Bitcoin, as it continues to grow its revenue and profits from its core business [2]. - Future investments will not only come from cash on hand but also from asset sales, partnerships, and financing opportunities [2]. - The company is considering a crypto-based rewards program as part of its pharmacy offerings, aiming to enhance financial resilience and create long-term value for shareholders [2]. Group 2: Company Overview - SRx Health Solutions, Inc. is an integrated Canadian healthcare services provider operating within the specialty healthcare industry, with a network that spans all ten Canadian provinces [3]. - The company combines industry knowledge, technology, and a patient-centric focus to develop strategies and solutions that improve patient care and wellness in Canada [3].

Group 1 - Baltic Horizon Fund is hosting an investor conference webinar on 15 May 2025 at 13:00 PM (CET) or 14:00 PM (EET) [1] - The webinar will be led by Tarmo Karotam, the Fund Manager, and will include a Q&A session [1] - Participants are encouraged to submit questions by 14 May 2025 to ensure they are addressed during the webinar [1] Group 2 - Registration for the webinar is available until 15 May at 12:00 PM (CET)/ 13:00 PM (EET) [2] - Registered participants will receive a reminder email one hour before the webinar starts [3] - The webinar will be recorded and made available on the company's website and Nasdaq Baltic YouTube account [3] Group 3 - For further inquiries, Tarmo Karotam can be contacted via email [4] - Baltic Horizon Fund is a registered contractual public closed-end real estate fund managed by Northern Horizon Capital AS [4] - The company encourages stakeholders to register for updates on projects and plans through its website [4]

Core Insights - Conduit Pharmaceuticals has secured a composition of matter patent for its lead asset, AZD1656, from the Korean Intellectual Property Office, enhancing its global intellectual property position and facilitating clinical development and strategic partnerships [1][2] - The patent approval follows similar grants in the U.S., Japan, and Australia, indicating a robust international patent strategy that supports Conduit's growth in the Asia-Pacific pharmaceutical market [1][2] - The company aims to leverage its innovative approach to compound development, utilizing artificial intelligence and cybernetics, to create long-term value through global partnerships and licensing deals [2] Company Overview - Conduit Pharmaceuticals is a clinical-stage life science company focused on developing Phase 2-ready assets through an integrated platform-driven approach [2] - The leadership team, including Dr. Andrew Regan and Dr. Freda Lewis-Hall, emphasizes a departure from traditional pharmaceutical business models by seeking exits through third-party licensing after successful clinical trials [2]

CALGARY, Alberta, May 09, 2025 (GLOBE NEWSWIRE) -- TSX: SHLE Source Energy Services Ltd. (“Source” or the “Company”) is pleased to announce that the Toronto Stock Exchange (the “TSX”) has accepted Source’s notice of intention to implement a Normal Course Issuer Bid (the “NCIB”). As of April 30, 2025, there were 13,545,055 Common Shares outstanding; however, pursuant to Source’s Term Loan agreement due December 20, 2029 (the “Term Loan”), Source is planning to acquire under the NCIB the lesser of $5 million ...

Core Viewpoint - 2025 is identified as a pivotal year for Standard Lithium, with significant milestones expected to shape the company's future and the lithium industry as a whole [2] Financial and Operational Highlights - The company finalized a $225 million grant from the U.S. Department of Energy to support the South West Arkansas Project [2][5] - Cash and working capital stood at $31.6 million and $31.3 million, respectively, as of March 31, 2025, with no term or revolving debt obligations [11] Project Developments - The South West Arkansas Project received special designation as a critical mineral production project under Executive Order 14241 [5] - Approval was granted for the brine production unit, named the Reynolds Unit, for Phase I of the South West Arkansas Project [5] - A royalty application was submitted to establish a lithium royalty for the Reynolds Unit [5] - Extensive field and reservoir testing was conducted, including drilling new wells and re-entering existing ones for detailed reservoir testing [5] - The final test of the field-pilot plant at the South West Arkansas Project demonstrated over 99% lithium recovery from brine [5] Strategic Initiatives - The company launched Smackover Lithium as the new name for its joint venture with Equinor, focusing on DLE projects in Southwest Arkansas and East Texas [5] - Continuous strategic additions to the board of directors were made, including the appointment of Karen G. Narwold as an independent member [5]